These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 16233969)
1. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. Cook AK; Bond KG J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845 [TBL] [Abstract][Full Text] [Related]
3. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism. Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. Vaughan MA; Feldman EC; Hoar BR; Nelson RW J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776 [TBL] [Abstract][Full Text] [Related]
5. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Bell R; Neiger R; McGrotty Y; Ramsey IK Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310 [TBL] [Abstract][Full Text] [Related]
6. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism. Kenefick SJ; Neiger R J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154 [TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE Vet Rec; 2008 Oct; 163(16):477-81. PubMed ID: 18931355 [TBL] [Abstract][Full Text] [Related]
8. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772 [TBL] [Abstract][Full Text] [Related]
9. Treatment of canine Alopecia X with trilostane. Cerundolo R; Lloyd DH; Persechino A; Evans H; Cauvin A Vet Dermatol; 2004 Oct; 15(5):285-93. PubMed ID: 15500480 [TBL] [Abstract][Full Text] [Related]
10. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment. Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism. Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of cortisol precursors for the diagnosis of pituitary-dependent hypercortisolism in dogs. Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE Vet Rec; 2008 May; 162(21):673-8. PubMed ID: 18503066 [TBL] [Abstract][Full Text] [Related]
13. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Ruckstuhl NS; Nett CS; Reusch CE Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311 [TBL] [Abstract][Full Text] [Related]
14. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Macfarlane L; Parkin T; Ramsey I Vet Rec; 2016 Dec; 179(23):597. PubMed ID: 27803375 [TBL] [Abstract][Full Text] [Related]
15. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism. Galac S; Buijtels JJCWM; Mol JA; Kooistra HS Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143 [TBL] [Abstract][Full Text] [Related]
16. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane. Midence JN; Drobatz KJ; Hess RS J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943 [TBL] [Abstract][Full Text] [Related]
17. The use of trilostane for the treatment of alopecia X in Alaskan malamutes. Leone F; Cerundolo R; Vercelli A; Lloyd DH J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187 [TBL] [Abstract][Full Text] [Related]
18. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats. Burkhardt WA; Guscetti F; Boretti FS; Ivos Todesco A; Aldajarov N; Lutz TA; Reusch CE; Sieber-Ruckstuhl NS Domest Anim Endocrinol; 2011 Apr; 40(3):155-64. PubMed ID: 21194873 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily. Arenas C; Melián C; Pérez-Alenza MD J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012). Woolcock AD; Bugbee AC; Creevy KE J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]